|
Press Releases |
|
|
|
Tuesday, March 26, 2024 |
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
Monday, December 11, 2023 |
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
more info >> |
|
Moderna公司回顧了在第二次環境、社會和治理(ESG)投資者活動中取得的進展和雄心 |
more info >> |
|
Wednesday, July 5, 2023 |
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
Wednesday, May 3, 2023 |
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
Tuesday, September 13, 2022 |
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
Friday, September 9, 2022 |
|
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines |
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing process of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
Tuesday, July 19, 2022 |
|
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. more info >> |
|
Thursday, February 17, 2022 |
|
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) |
Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
華住公佈2024年第一季度財報 收入增長17.8%优于预期
May 17, 2024 22:39 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
卓悦集团附属公司与“湖南广电芒果超媒”旗下“快乐购”签署战略合作备忘录
May 17, 2024 20:00 HKT/SGT
|
|
|
卓悅集團附屬公司與「湖南廣電芒果超媒」旗下「快樂購」簽署戰略合作備忘錄
May 17, 2024 19:43 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
中信国际电讯CPC守正创新 AI创新方案喜迎两大奖
May 17, 2024 17:04 HKT/SGT
|
|
|
中信國際電訊CPC守正創新 AI創新方案喜迎兩大獎
May 17, 2024 16:55 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
富士通、論理推論を可能とする大規模言語モデルの研究開発が「GENIAC」に採択
May 17, 2024 14:00: JST
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
|
More News >> |
|
|
|
|
|